Depression: When to See a Doctor, Causes, and Treatment Options

What Is Depression and How Common Is It?

Depression is not the same as a few bad days. Major Depressive Disorder is a clinical syndrome defined by persistent changes in mood, cognition, sleep, appetite, and energy that last at least two weeks and interfere with daily life. The World Health Organization estimated in 2023 that 280 million people worldwide live with depression, making it one of the leading causes of disability globally.

The spectrum of depressive illness

The term "depression" covers a family of disorders. Major Depressive Disorder is the most studied form. Persistent Depressive Disorder (dysthymia) involves lower-grade symptoms lasting two or more years. Seasonal Affective Disorder follows a recurring seasonal pattern, most often worsening in autumn and winter. Postpartum depression affects roughly 1 in 8 women after childbirth, according to CDC surveillance data.

Each subtype has its own treatment nuances, but all share the same biological core: dysregulation of monoamine neurotransmitters, hypothalamic-pituitary-adrenal (HPA) axis stress responses, and neuroplasticity in the prefrontal cortex and hippocampus.

Why depression is under-diagnosed

The U.S. Preventive Services Task Force recommends screening all adults for depression in primary care settings using a validated tool such as the PHQ-9. Despite this, a significant number of patients go undiagnosed for years. Stigma, the misattribution of symptoms to stress or fatigue, and limited access to mental health care all contribute.

What Causes Depression?

No single cause produces depression. The condition emerges from a combination of genetic vulnerability, neurobiological changes, life events, and medical or hormonal factors acting together over time.

Genetic and neurobiological factors

First-degree relatives of people with MDD have a two to three times higher lifetime risk than the general population, according to a large twin-study meta-analysis published in Psychological Medicine. Genome-wide association studies have now identified more than 100 genetic loci associated with MDD risk, though no single gene determines outcome.

At the neurochemical level, reduced synaptic availability of serotonin, norepinephrine, and dopamine in limbic circuits is the best-characterized mechanism, and it is the target of most pharmacological treatments. Chronic elevation of cortisol through HPA-axis overdrive also damages hippocampal neurons, which may explain memory and concentration deficits in depressed patients.

Psychosocial and environmental triggers

Adverse childhood experiences (ACEs), chronic stress, grief, relationship breakdown, financial strain, and social isolation are well-documented risk factors. A 2017 analysis in JAMA Psychiatry found that childhood maltreatment nearly doubled the odds of developing recurrent MDD in adulthood compared with matched controls.

Loneliness and social disconnection activate the same brain regions that register physical pain, a finding replicated across neuroimaging studies.

Medical and hormonal contributors

Thyroid dysfunction, particularly hypothyroidism, can produce a clinical picture almost identical to MDD. Testosterone deficiency in men and estrogen fluctuation across the perimenopause are independently associated with depressive symptoms. Chronic pain, inflammatory conditions such as rheumatoid arthritis, diabetes, and cardiovascular disease all carry substantially elevated rates of comorbid depression.

Certain medications, including beta-blockers, corticosteroids, isotretinoin, and some hormonal contraceptives, have depression listed among their adverse effects. Any patient with new-onset depressive symptoms should have a medication review alongside basic labs (TSH, CBC, CMP, and vitamin D).

Recognizing the Symptoms: What to Watch For

The DSM-5 requires five or more of the following nine criteria, present nearly every day for at least two weeks, with at least one being depressed mood or loss of interest:

1. Depressed mood most of the day
2. Markedly diminished interest or pleasure in activities (anhedonia)
3. Significant weight change (more than 5% body weight in one month) or appetite disturbance
4. Insomnia or hypersomnia
5. Psychomotor agitation or retardation observable by others
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive guilt
8. Difficulty concentrating or making decisions
9. Recurrent thoughts of death, suicidal ideation, or a specific plan

A full description of these criteria appears in the DSM-5-TR and is also summarized in the NIMH depression overview.

Atypical presentations to know

Depression does not always look like sadness. In older adults, irritability, somatic complaints such as unexplained pain, and cognitive slowing frequently predominate over reported low mood. In adolescents, the DSM-5 allows irritable mood to substitute for depressed mood as a core criterion.

Men are more likely to express depression as anger, risk-taking behavior, or substance use rather than tearfulness. Missing this pattern delays diagnosis by an average of four years, based on data from the National Comorbidity Survey Replication.

Using the PHQ-9 to track severity

The Patient Health Questionnaire-9 (PHQ-9) is the most widely used validated screening and monitoring instrument in primary care. Scores of 5, 10, 15, and 20 correspond to mild, moderate, moderately severe, and severe depression respectively. A score at or above 10 has a sensitivity of 88% and specificity of 88% for MDD, as validated in the original Kroenke et al. 2001 publication in the Journal of General Internal Medicine.

When to See a Doctor: Specific Thresholds

Most guidelines suggest evaluation after two consecutive weeks of symptoms that interfere with work, relationships, or self-care. Waiting is rarely beneficial and often allows the episode to deepen.

Non-emergency situations that still warrant prompt care

• Persistent low mood or anhedonia for 14 days or more, even if you can still function
• Sleep or appetite disruption lasting more than two weeks without a clear explanation
• Difficulty concentrating at work or school that was not present six months ago
• A PHQ-9 score of 10 or above, even if you are not sure the symptoms are "bad enough"
• A first depressive episode in the context of a new medication, a hormonal transition (perimenopause, postpartum), or a new medical diagnosis

The American Psychiatric Association's Practice Guideline for the Treatment of Patients with MDD states: "Patients with MDD should be assessed at regular intervals to monitor treatment response, side effects, and the emergence of new symptoms." APA Practice Guidelines reflect the consensus that early, proactive engagement with care produces better long-term outcomes than crisis-driven treatment.

When to seek same-day care

Go to an urgent care clinic or emergency department, or call 988 (Suicide and Crisis Lifeline), if any of the following are present:

• Suicidal thoughts with a specific plan or intent to act
• Self-harm behavior that has already occurred
• Inability to care for oneself, including not eating, not sleeping for multiple days, or being unable to leave bed
• Psychotic features such as hallucinations or delusional beliefs alongside depressed mood
• Severe agitation that poses a safety risk to yourself or others

Passive thoughts such as "I wish I weren't here" are still worth disclosing to a clinician, but they do not automatically require an emergency visit. Active suicidal ideation with intent does.

The HealthRX clinical team uses a three-tier triage framework for depression: Tier 1 (PHQ-9 <10, symptoms <2 weeks, no functional impairment) calls for watchful waiting with scheduled follow-up at two weeks; Tier 2 (PHQ-9 10-19, symptoms 2 or more weeks, mild-to-moderate functional impairment) warrants same-week primary care or telehealth evaluation and initiation of structured psychotherapy or pharmacotherapy; Tier 3 (PHQ-9 ≥20, active suicidal ideation, or psychotic features) requires same-day or emergency-level care.

How Is Depression Diagnosed?

There is no blood test for MDD. Diagnosis is clinical, based on a structured interview, a validated questionnaire such as the PHQ-9, and the exclusion of medical mimics.

The clinical interview and differential diagnosis

A thorough evaluation includes current symptoms, duration, and impairment; personal and family psychiatric history; substance use history; current medications; and a targeted medical history to rule out thyroid disease, anemia, sleep apnea, and other conditions that produce overlapping symptoms.

Lab work typically includes TSH, a complete blood count, a comprehensive metabolic panel, and 25-OH vitamin D. Some clinicians add a fasting lipid panel and hemoglobin A1c, given the bidirectional relationship between metabolic disease and depression noted in a 2018 Lancet Psychiatry review.

Ruling out bipolar disorder

Prescribing an antidepressant to someone with undiagnosed Bipolar Disorder can trigger a manic episode. Before starting any antidepressant, clinicians should screen for a personal or family history of mania, hypomania, or rapid cycling mood. The Mood Disorder Questionnaire (MDQ) is a widely used eight-minute screen. The American Academy of Family Physicians recommends this step as standard practice before antidepressant initiation.

Treatment for Depression: What the Evidence Shows

Treatment choice depends on symptom severity, patient preference, prior treatment history, and the presence of comorbid conditions.

Psychotherapy

Cognitive Behavioral Therapy (CBT) is the best-studied psychotherapy for MDD. A 2019 Cochrane review of 115 trials (N=6,699) found CBT significantly more effective than control conditions, with a standardized mean difference of -0.95 (95% CI -1.12 to -0.78) for depressive symptoms. The full review is available at Cochrane Library.

Behavioral Activation, Interpersonal Therapy (IPT), and Problem-Solving Therapy each show comparable efficacy to CBT in head-to-head trials. Therapy is generally delivered in 12 to 20 weekly sessions, though shorter formats (8 sessions) can work for mild-to-moderate presentations.

Antidepressant medications

SSRIs are first-line pharmacotherapy for MDD per APA, NICE, and most national guidelines. Commonly prescribed options include:

• Sertraline (Zoloft): Starting dose 50 mg/day, target 100-200 mg/day
• Escitalopram (Lexapro): Starting dose 10 mg/day, target 10-20 mg/day
• Fluoxetine (Prozac): Starting dose 10-20 mg/day, target 20-60 mg/day

The large STAR*D trial (N=2,876) remains the most informative effectiveness study of antidepressant sequencing. In Level 1 (citalopram monotherapy), 28% of participants achieved remission at the end of the acute treatment phase. STAR*D results published in the American Journal of Psychiatry also showed that roughly 50% of those who did not remit in Level 1 achieved remission after switching to or augmenting with a second agent.

SNRIs (venlafaxine, duloxetine) are often chosen when comorbid anxiety, pain, or fibromyalgia is present. Bupropion is preferred when sexual dysfunction or weight gain must be minimized. Mirtazapine is useful when insomnia and weight loss are prominent.

Antidepressants typically require four to six weeks before full therapeutic effect is apparent. Patients should be reassessed at two-week intervals during the first two months of treatment, per FDA prescribing guidance on antidepressant monitoring.

Combination therapy

The combination of antidepressant medication plus psychotherapy outperforms either treatment alone in moderate-to-severe MDD. A landmark NEJM-published trial by Keller et al. (N=681) found that combined nefazodone and CBASP psychotherapy produced response rates of 73% compared with 48% and 48% for each monotherapy arm, respectively.

For patients who do not respond after two adequate antidepressant trials, psychiatry referral is standard. Options at that stage include augmentation with lithium, atypical antipsychotics (aripiprazole, quetiapine), or newer agents such as esketamine (Spravato), which the FDA approved in 2019 for treatment-resistant depression based on TRANSFORM-2 trial data.

Lifestyle and adjunctive interventions

Physical exercise has a measurable antidepressant effect. A 2016 Cochrane review (N=1,487, 35 trials) found exercise superior to control conditions with a moderate effect size. The analysis is indexed at PubMed. Aerobic exercise at 30 minutes, three to five times per week, is the best-studied protocol.

Sleep normalization, alcohol reduction, omega-3 supplementation (EPA-dominant, 1-2 g/day), and bright-light therapy for seasonal presentations each carry supporting evidence, though effect sizes are smaller than those for CBT or SSRIs.

Special Populations and Considerations

Postpartum depression

The FDA approved brexanolone (Zulresso) in 2019 as the first drug specifically indicated for postpartum depression. A 60-hour IV infusion produced significant symptom reduction compared to placebo in Phase 3 trials, as reported in The Lancet. Oral zuranolone (Zurzuvae) received FDA approval in 2023 as a 14-day course and provides a more accessible option. Standard SSRIs remain compatible with breastfeeding for most women, with sertraline having the lowest relative infant dose in breast milk.

Adolescents

Fluoxetine is the only SSRI with FDA approval for MDD in patients as young as 8 years of age. The FDA mandates a black-box warning about increased suicidal thinking in patients age 24 and younger during the first weeks of antidepressant treatment. This does not mean antidepressants cause suicide; it means closer monitoring is required. The TADS trial (N=439) found that combination fluoxetine plus CBT produced a 71% response rate in adolescents, higher than either treatment alone.

Older adults

Older patients tolerate SSRIs but are at higher risk of hyponatremia, falls from orthostatic hypotension, and drug-drug interactions given polypharmacy. Sertraline and escitalopram have the cleanest interaction profiles among the SSRIs in this population. Tricyclic antidepressants (TCAs) should generally be avoided in adults over 65 because of anticholinergic burden. The American Geriatrics Society Beers Criteria explicitly lists most TCAs as potentially inappropriate in older patients.

Long-Term Management and Relapse Prevention

A single depressive episode carries a 50% lifetime risk of a second episode. After two episodes, that risk climbs to 80%. After three, recurrence is nearly certain without maintenance treatment, according to data summarized in the NIMH's research page on depression.

Current APA guidelines recommend continuing antidepressant therapy for at least six to twelve months after full symptom remission for a first episode. Patients with two or more lifetime episodes are candidates for indefinite maintenance therapy. Abrupt discontinuation of SSRIs and SNRIs frequently causes discontinuation syndrome, characterized by dizziness, flu-like symptoms, and irritability; all tapers should be gradual, typically over four or more weeks.

Continuation of psychotherapy, particularly CBT, after acute-phase treatment significantly reduces relapse rates. A meta-analysis in JAMA Psychiatry found that patients who received continuation CBT after antidepressant response had a 44% lower risk of relapse over a two-year follow-up compared to those who discontinued therapy.